Track topics on Twitter Track topics that are important to you
]]>(MedPage Today) -- Single-agent BRAF inhibition produced viable objective responses in patients with non-small-cell lung cancer (NSCLC) and certain BRAF mutations, a phase II trial showed. After a median follow-up of 23.9 months, 44.8% of 96 evaluable...
Original Article: 'Viable' Responses With BRAF Inhibitor in Lung CancerNEXT ARTICLE
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...